Long Non-coding RNA CASC15 Promotes Intrahepatic Cholangiocarcinoma Possibly through Inducing PRDX2/PI3K/AKT Axis. 2021

Yuan Zhang, and Lufei Zhang, and Sinan Lu, and Yucheng Xiang, and Cheng Zeng, and Tianyu He, and Yuan Ding, and Weilin Wang
Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

OBJECTIVE Intrahepatic cholangiocarcinoma (ICC) is one of the most common liver primary tumors but its treatments are limited. Bioinformatics showed that the expression level of long non-coding RNA cancer-associated susceptibility 15 gene (CASC15) is correlated with ICC progression, but its functional mechanism remains unclear. METHODS Tissues from ICC patients, tumor and adjacent tissue, were used for detection of the expression of CASC15. Clinical data were also collected for clinicopathologic and survival analysis. Short interfering RNA and lentiviral short hairpin RNA were used to knock down CASC15 and PRDX2 expression in ICC cell lines, for the analysis of changes of cell function and xenografts. RNA-pulldown and RNA immunoprecipitation assays were used to detect RNA-binding protein, PRDX2. Male nude mice were used for ICC xenografts, and livers were collected after 4 weeks for immunohistochemistry. RESULTS CASC15 is highly expressed in ICC tissues and is related to higher TNM stage. Knockdown of CASC15 in ICC cells reduced cell proliferation, migration, invasiveness and increased apoptosis, and G1/S block. PRDX2 bound to CASC15. Knockdown of CASC15 decreased PRDX2 expression which was rescued by the inhibition of proteasome formation. Downregulation of PRDX2 resulted in G1/S block, reduced ICC cell invasion. Downregulation of CASC15 inhibited phosphoinositide 3-kinase (PI3K)/AKT/c-Myc pathway through downregulating of PRDX2 and overexpressed PRDX2 rescued the block. CASC15 knockout in ICC xenografts suppressed tumor development in vivo, decreased the expression of PRDX2 and Ki67 and inhibited PI3K/AKT pathway. CONCLUSIONS CASC15 promotes ICC possibly by targeting PRDX2 via the PI3K/AKT pathway, indicating poor prognosis and high degree of malignancy of ICC.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014162 Transfection The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES. Transfections
D051057 Proto-Oncogene Proteins c-akt Protein-serine-threonine kinases that contain PLECKSTRIN HOMOLOGY DOMAINS and are activated by PHOSPHORYLATION in response to GROWTH FACTORS or INSULIN. They play a major role in cell metabolism, growth, and survival as a core component of SIGNAL TRANSDUCTION. Three isoforms have been described in mammalian cells. akt Proto-Oncogene Protein,c-akt Protein,AKT1 Protein Kinase,AKT2 Protein Kinase,AKT3 Protein Kinase,Akt-alpha Protein,Akt-beta Protein,Akt-gamma Protein,Protein Kinase B,Protein Kinase B alpha,Protein Kinase B beta,Protein Kinase B gamma,Protein-Serine-Threonine Kinase (Rac),Proto-Oncogene Protein Akt,Proto-Oncogene Protein RAC,Proto-Oncogene Proteins c-akt1,Proto-Oncogene Proteins c-akt2,Proto-Oncogene Proteins c-akt3,RAC-PK Protein,Rac Protein Kinase,Rac-PK alpha Protein,Rac-PK beta Protein,Related to A and C-Protein,c-akt Proto-Oncogene Protein,Akt alpha Protein,Akt beta Protein,Akt gamma Protein,Akt, Proto-Oncogene Protein,Protein, akt Proto-Oncogene,Protein, c-akt Proto-Oncogene,Proteins c-akt1, Proto-Oncogene,Proteins c-akt2, Proto-Oncogene,Proteins c-akt3, Proto-Oncogene,Proto Oncogene Protein Akt,Proto Oncogene Protein RAC,Proto Oncogene Proteins c akt,Proto Oncogene Proteins c akt1,Proto Oncogene Proteins c akt2,Proto Oncogene Proteins c akt3,Proto-Oncogene Protein, akt,Proto-Oncogene Protein, c-akt,RAC PK Protein,RAC, Proto-Oncogene Protein,Rac PK alpha Protein,Rac PK beta Protein,Related to A and C Protein,akt Proto Oncogene Protein,alpha Protein, Rac-PK,c akt Proto Oncogene Protein,c-akt, Proto-Oncogene Proteins,c-akt1, Proto-Oncogene Proteins,c-akt2, Proto-Oncogene Proteins,c-akt3, Proto-Oncogene Proteins
D062085 RNA, Long Noncoding A class of untranslated RNA molecules that are typically greater than 200 nucleotides in length and do not code for proteins. Members of this class have been found to play roles in transcriptional regulation, post-transcriptional processing, CHROMATIN REMODELING, and in the epigenetic control of chromatin. LincRNA,RNA, Long Untranslated,LINC RNA,LincRNAs,Long Intergenic Non-Protein Coding RNA,Long Non-Coding RNA,Long Non-Protein-Coding RNA,Long Noncoding RNA,Long ncRNA,Long ncRNAs,RNA, Long Non-Translated,lncRNA,Long Intergenic Non Protein Coding RNA,Long Non Coding RNA,Long Non Protein Coding RNA,Long Non-Translated RNA,Long Untranslated RNA,Non-Coding RNA, Long,Non-Protein-Coding RNA, Long,Non-Translated RNA, Long,Noncoding RNA, Long,RNA, Long Non Translated,RNA, Long Non-Coding,RNA, Long Non-Protein-Coding,Untranslated RNA, Long,ncRNA, Long,ncRNAs, Long
D018281 Cholangiocarcinoma A malignant tumor arising from the epithelium of the BILE DUCTS. Cholangiocellular Carcinoma,Extrahepatic Cholangiocarcinoma,Intrahepatic Cholangiocarcinoma,Carcinoma, Cholangiocellular,Carcinomas, Cholangiocellular,Cholangiocarcinoma, Extrahepatic,Cholangiocarcinoma, Intrahepatic,Cholangiocarcinomas,Cholangiocarcinomas, Extrahepatic,Cholangiocarcinomas, Intrahepatic,Cholangiocellular Carcinomas,Extrahepatic Cholangiocarcinomas,Intrahepatic Cholangiocarcinomas
D019869 Phosphatidylinositol 3-Kinases Phosphotransferases that catalyzes the conversion of 1-phosphatidylinositol to 1-phosphatidylinositol 3-phosphate. Many members of this enzyme class are involved in RECEPTOR MEDIATED SIGNAL TRANSDUCTION and regulation of vesicular transport with the cell. Phosphatidylinositol 3-Kinases have been classified both according to their substrate specificity and their mode of action within the cell. PI-3 Kinase,Phosphatidylinositol-3-OH Kinase,PtdIns 3-Kinase,PI 3-Kinase,PI-3K,PI3 Kinases,PI3-Kinase,Phosphoinositide 3 Kinases,Phosphoinositide 3-Hydroxykinase,PtdIns 3-Kinases,3-Hydroxykinase, Phosphoinositide,Kinase, PI-3,Kinase, Phosphatidylinositol-3-OH,Kinases, PI3,Kinases, Phosphoinositide 3,PI 3 Kinase,PI3 Kinase,Phosphatidylinositol 3 Kinases,Phosphatidylinositol 3 OH Kinase,Phosphoinositide 3 Hydroxykinase,PtdIns 3 Kinase,PtdIns 3 Kinases

Related Publications

Yuan Zhang, and Lufei Zhang, and Sinan Lu, and Yucheng Xiang, and Cheng Zeng, and Tianyu He, and Yuan Ding, and Weilin Wang
August 2018, Environmental science and pollution research international,
Yuan Zhang, and Lufei Zhang, and Sinan Lu, and Yucheng Xiang, and Cheng Zeng, and Tianyu He, and Yuan Ding, and Weilin Wang
July 2019, Experimental and therapeutic medicine,
Yuan Zhang, and Lufei Zhang, and Sinan Lu, and Yucheng Xiang, and Cheng Zeng, and Tianyu He, and Yuan Ding, and Weilin Wang
January 2018, Cell & bioscience,
Yuan Zhang, and Lufei Zhang, and Sinan Lu, and Yucheng Xiang, and Cheng Zeng, and Tianyu He, and Yuan Ding, and Weilin Wang
January 2021, Current pharmaceutical design,
Yuan Zhang, and Lufei Zhang, and Sinan Lu, and Yucheng Xiang, and Cheng Zeng, and Tianyu He, and Yuan Ding, and Weilin Wang
October 2018, Biochemical and biophysical research communications,
Yuan Zhang, and Lufei Zhang, and Sinan Lu, and Yucheng Xiang, and Cheng Zeng, and Tianyu He, and Yuan Ding, and Weilin Wang
April 2020, Journal of hepatology,
Yuan Zhang, and Lufei Zhang, and Sinan Lu, and Yucheng Xiang, and Cheng Zeng, and Tianyu He, and Yuan Ding, and Weilin Wang
August 2017, Clinical and experimental pharmacology & physiology,
Yuan Zhang, and Lufei Zhang, and Sinan Lu, and Yucheng Xiang, and Cheng Zeng, and Tianyu He, and Yuan Ding, and Weilin Wang
August 2025, Cell & bioscience,
Yuan Zhang, and Lufei Zhang, and Sinan Lu, and Yucheng Xiang, and Cheng Zeng, and Tianyu He, and Yuan Ding, and Weilin Wang
February 2022, Digestive diseases and sciences,
Yuan Zhang, and Lufei Zhang, and Sinan Lu, and Yucheng Xiang, and Cheng Zeng, and Tianyu He, and Yuan Ding, and Weilin Wang
November 2025, Molecular cancer research : MCR,
Copied contents to your clipboard!